2026 — Shared latent genetic liability across FM, insomnia, depression, anxiety
One-paragraph summary
Genomic structural equation modeling (gSEM) study identifying a shared latent genetic factor — mvFibroPsych — across phenotype-specific GWAS meta-analyses for fibromyalgia, insomnia, depression, and anxiety. Lead SNPs and associated genes annotated via FUMA; gene-set and tissue enrichment analyses; Latent Causal Variable (LCV) method applied to identify modifiable risk factors. For the project, this paper directly extends Kerrebijn 2025's FM GWAS finding into multi-trait shared-genetic-architecture analysis — operationalizing what Hypothesis 2's heritable predictive-coding substrate predicts (FM should share genetic architecture with PTSD, IBS, and depression-spectrum conditions per Kerrebijn's rg > 0.7 correlations). The mvFibroPsych latent factor is a candidate population-level construct that the project should track.
Claims as triples
fm_central_only — correlates_with → depression[evidence: gSEM shared latent factor mvFibroPsych; confidence: emerging (reinforces existing edge with new genetic-architecture data)]fm_central_only — correlates_with → anxiety[evidence: gSEM shared latent factor; confidence: emerging]fm_central_only — correlates_with → insomnia[evidence: gSEM shared latent factor — confirms B5 bridge at genetic level; confidence: emerging]predictive_coding_failure — bridges → fm_central_only[evidence: shared CNS genetic substrate across mvFibroPsych traits; confidence: emerging (reinforces Kerrebijn 2025 anchor)]
Triangulation notes
- Directly extends Kerrebijn 2025 (the load-bearing Hypothesis 2 GWAS anchor) into multi-trait shared-genetic-architecture territory.
- Adds insomnia to the genetic-correlation set — strengthens B5 bridge (glymphatic + sleep + neuroinflammation) at the population-genetic level.
- mvFibroPsych as a new candidate construct for Hypothesis 2's substrate — worth tracking for future v0.4 white-paper integration.
- Discovered via Probe 1 (epigenetic clock / biological age); scored ingestion-worthy; promoted in Recommendation 3.